Replies to post #69739 on Biotech Values

[DewDiligence]

>MRX Solodyn – It appears that we now know of another filler: Mylan<

MRX will almost certainly settle, IMO. In these kinds of cases, the branded company either litigates all challenges or settles all challenges—rarely does it make sense to mix and match.